The motivation behind the work lies in one of the most stubborn puzzles of modern medicine. Neurodegenerative diseases such as Parkinson’s and Alzheimer’s are rising sharply in developed countries, and while their causes are multifactorial, accumulating evidence implicates environmental metal exposure as a contributing factor. Manganese, the third most abundant transition metal in the Earth’s crust, is an essential trace nutrient that supports enzymes ranging from glutamine synthetase to superoxide dismutase, yet overexposure—common among miners, welders, and mechanics—produces a syndrome called manganism, marked by motor dysfunction, hallucinations, and psychosis that closely resembles Parkinson’s disease but is progressive and largely irreversible. Aluminium, the most plentiful metal in the crust, has no known biological role in the human body, yet it has been repeatedly linked in the literature to Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, making both metals legitimate targets for protective interventions.

The toxicological mechanisms of these two metals are well characterized but distinct. Manganese accumulates in mitochondria, where it disrupts oxidative phosphorylation, elevates the production of reactive oxygen species, and destabilizes the mitochondrial membrane potential. It also derails neurotransmitter homeostasis—flooding the extracellular space with glutamate while depleting dopamine and disturbing γ-aminobutyric acid levels—and perturbs iron homeostasis and apoptotic signaling. Aluminium works through a different toolkit: it promotes free radical formation in astrocytes and microglia, amplifies iron-driven lipid peroxidation through the Fenton reaction, and mimics magnesium and calcium to corrupt ion-dependent processes. It also stokes inflammation, triggering the release of tumour necrosis factor-α, interleukin 1, and macrophage inflammatory protein-1α. Both metals, in short, attack neurons along multiple fronts simultaneously, which is precisely why broad-spectrum antioxidants like polyphenols have attracted such interest as potential countermeasures.

To test that idea, the Kraków team turned to SH-SY5Y cells, a human neuroblastoma line that has become a standard in vitro model for studying neurotoxicity in human-derived tissue. The experimental design was deliberately realistic in one key respect: rather than testing only the parent compounds, the researchers also examined trans-resveratrol 3-O-β-D-glucuronide and quercetin 3-O-β-D-glucuronide—the conjugated forms that the liver and intestine actually generate when people consume these polyphenols. Cells were pretreated with each compound at 5, 10, 20, or 30 micromolar for 24 hours, then exposed for another 24 hours to manganese(II) chloride tetrahydrate at 3 millimolar or aluminium L-lactate at 10 millimolar. The researchers then measured three readouts: lactate dehydrogenase release as a marker of membrane integrity, thiazolyl blue tetrazolium bromide reduction as a proxy for mitochondrial metabolic activity, and caspase-3 activity as an indicator of apoptosis.

The baseline toxicity results confirmed the destructive power of both metals. Manganese significantly elevated LDH release and depressed MTT reduction, while also driving a robust increase in caspase-3 activity—a signature consistent with apoptosis as the dominant mode of manganese-induced cell death. Aluminium likewise compromised membrane integrity and mitochondrial function, but, intriguingly, it reduced caspase-3 activity rather than raising it. The authors suggest that under their experimental conditions, aluminium’s neurotoxicity may not be mediated by caspase-dependent apoptosis at all, but rather by necrosis, a possibility supported by earlier work showing that aluminium compounds can switch cells from apoptotic to necrotic death as concentrations rise. This divergence matters, because it means a protective compound that rescues cells from one metal may be useless against the other, even when both metals damage the same cellular machinery.

Against manganese, the protective profile was clear and, in places, unexpected. Quercetin at 5 and 10 micromolar prevented the metal-induced surge in LDH efflux, and quercetin at 5, 10, and 20 micromolar normalized caspase-3 activity—evidence that the flavonoid shielded both membranes and apoptotic signaling. The glucuronidated metabolites also proved effective, but only at higher doses: both trans-resveratrol 3-O-β-D-glucuronide and quercetin 3-O-β-D-glucuronide at 20 and 30 micromolar reduced manganese-driven LDH release. Trans-resveratrol itself, however, was a disappointment on the membrane front, failing to protect LDH secretion at any dose and actually worsening manganese’s suppression of MTT reduction at 5, 20, and 30 micromolar. Only at the lowest concentration of 5 micromolar did trans-resveratrol restore caspase-3 activity to normal levels, hinting at a narrow therapeutic window for the stilbene compound.

The aluminium experiments told a different story. Here, the parent compounds shone at low concentrations: trans-resveratrol and quercetin, both at 5 and 10 micromolar, significantly diminished the metal’s disruption of LDH efflux, while trans-resveratrol at 20 micromolar actually aggravated the damage—a textbook example of the dose-dependent reversal that has haunted polyphenol pharmacology. The glucuronides were largely sidelined: trans-resveratrol 3-O-β-D-glucuronide helped only at 30 micromolar, and quercetin 3-O-β-D-glucuronide, though ineffective on membrane integrity, was the sole compound to improve MTT reduction, at 5 micromolar. Most tellingly, none of the four polyphenols recovered the aluminium-evoked disturbance of caspase-3 activity, reinforcing the suspicion that aluminium kills these cells through pathways that antioxidant pretreatment cannot readily intercept within the caspase cascade.

Why would the parent compounds outperform their metabolites, and why would lower doses beat higher ones? The authors point to a growing body of evidence that structural modifications such as glucuronidation can fundamentally alter polyphenol bioactivity. Resveratrol’s antithrombotic effects in activated endothelial cells, for instance, are not reproduced by its metabolites, and curcumin—but not curcumin-glucuronide—inhibits transforming growth factor-β signaling in bone metastatic breast cancer cells. One plausible mechanism, proposed by researchers studying quercetin in oxidative stress models, is that conjugated forms must first be deconjugated back to their aglycone by β-glucuronidase enzymes from microglial cells before they can protect neurons. The dose-dependence has its own explanation: quercetin, in scavenging free radicals, is itself degraded into orthoquinone species that can become hazardous to cells, meaning that at high concentrations the compound may shift from antioxidant to pro-oxidant. Similar biphasic behavior has been documented for resveratrol in dopamine-treated SH-SY5Y cells, where protection peaked at low doses and harm emerged at higher ones.

The authors are candid about the limitations of their work. Only single concentrations of each metal were tested, the polyphenol dose range was narrow, and the exposure windows were fixed at 24 and 48 hours, potentially missing optimal timing for some cellular processes. The molecular mechanisms underlying the observed protection—whether involving reactive oxygen species scavenging, glutathione redox status, mitochondrial membrane potential, or inflammatory cytokine modulation—remain unmeasured, and the SH-SY5Y model, while valuable, cannot fully replicate the complexity of the living brain. Still, the study represents basic research with clear translational implications: it confirms that trans-resveratrol, quercetin, and their glucuronidated metabolites hold genuine neuroprotective potential against manganese and aluminium toxicity, while cautioning that the form and concentration of these compounds are not trivial details but decisive variables. As interest in dietary polyphenols as preventive agents for neurodegenerative disease continues to grow, this work offers both a promising lead and a sobering reminder that in the chemistry of plant antioxidants, more is not always better—and sometimes, the body’s own metabolites hold part of the answer.

Subject of Research: Neuroprotective effects of dietary polyphenols against manganese- and aluminium-induced cytotoxicity in human neuroblastoma cells

Article Title: Protective effects of resveratrol, quercetin, and their glucuronide derivatives in an in vitro model of Mn- and Al-induced cytotoxicity in SH-SY5Y human neuroblastoma cells

Article References: Protective effects of resveratrol, quercetin, and their glucuronide derivatives in an in vitro model of Mn- and Al-induced cytotoxicity in SH-SY5Y human neuroblastoma cells. (n.d.). https://doi.org/10.1007/s44339-025-00029-7

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00029-7

Keywords: resveratrol, quercetin, glucuronide metabolites, manganese toxicity, aluminium toxicity, SH-SY5Y cells, neuroprotection, neurotoxicity, polyphenols, oxidative stress, apoptosis, caspase-3